MedKoo Cat#: 461373 | Name: Epiroprim

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Epiroprim is an analog of trimethoprim and an inhibitor of dihydrofolate reductase.

Chemical Structure

Epiroprim
Epiroprim
CAS#73090-70-7

Theoretical Analysis

MedKoo Cat#: 461373

Name: Epiroprim

CAS#: 73090-70-7

Chemical Formula: C19H23N5O2

Exact Mass: 353.1852

Molecular Weight: 353.42

Elemental Analysis: C, 64.57; H, 6.56; N, 19.82; O, 9.05

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Epiroprim; Epiroprime; Ro 11-8958; Ro-11-8958; Ro11-8958;
IUPAC/Chemical Name
5-(3,5-diethoxy-4-(1H-pyrrol-1-yl)benzyl)pyrimidine-2,4-diamine
InChi Key
NMARPFMJVCXSAV-UHFFFAOYSA-N
InChi Code
InChI=1S/C19H23N5O2/c1-3-25-15-10-13(9-14-12-22-19(21)23-18(14)20)11-16(26-4-2)17(15)24-7-5-6-8-24/h5-8,10-12H,3-4,9H2,1-2H3,(H4,20,21,22,23)
SMILES Code
CCOC1=C(N2C=CC=C2)C(OCC)=CC(CC3=CN=C(N)N=C3N)=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 353.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Martinez A, Allegra CJ, Kovacs JA. Efficacy of epiroprim (Ro11-8958), a new dihydrofolate reductase inhibitor, in the treatment of acute Toxoplasma infection in mice. Am J Trop Med Hyg. 1996 Mar;54(3):249-52. PubMed PMID: 8600759. 2: Dhople AM. In vitro activity of epiroprim, a dihydrofolate reductase inhibitor, singly and in combination with brodimoprim and dapsone, against Mycobacterium leprae. Int J Antimicrob Agents. 1999 Aug;12(4):319-23. PubMed PMID: 10493608. 3: Chang HR, Arsenijevic D, Comte R, Polak A, Then RL, Pechère JC. Activity of epiroprim (Ro 11-8958), a dihydrofolate reductase inhibitor, alone and in combination with dapsone against Toxoplasma gondii. Antimicrob Agents Chemother. 1994 Aug;38(8):1803-7. PubMed PMID: 7986011; PubMed Central PMCID: PMC284639. 4: Luttringer O, Theil FP, Poulin P, Schmitt-Hoffmann AH, Guentert TW, Lavé T. Physiologically based pharmacokinetic (PBPK) modeling of disposition of epiroprim in humans. J Pharm Sci. 2003 Oct;92(10):1990-2007. PubMed PMID: 14502539. 5: Locher HH, Schlunegger H, Hartman PG, Angehrn P, Then RL. Antibacterial activities of epiroprim, a new dihydrofolate reductase inhibitor, alone and in combination with dapsone. Antimicrob Agents Chemother. 1996 Jun;40(6):1376-81. PubMed PMID: 8726004; PubMed Central PMCID: PMC163334. 6: Lee HS, Chang HR, Khoo YM. Simple HPLC determination of the concentrations of epiroprim in the serum and brains of mice. J Pharm Pharmacol. 1996 Oct;48(10):1090-2. PubMed PMID: 8953514. 7: N'guessan K, Dosso M, Marchal G, Chavarot P, Romain F, Pescher P, Edy. [Preliminary study on isoniazid-epiroprim combination in a tuberculosis murine model]. Bull Soc Pathol Exot. 2002 Nov;95(4):265-8. French. PubMed PMID: 12596375. 8: Dosso M, Ouattara L, Cherif AM, Bouzid SA, Haller L, Fernex M. Experimental in vitro efficacy study on the interaction of epiroprim plus isoniazid against Mycobacterium tuberculosis. Chemotherapy. 2001 Mar-Apr;47(2):123-7. PubMed PMID: 11173814. 9: Mehlhorn H, Dankert W, Hartman PG, Then RL. A pilot study on the efficacy of epiroprim against developmental stages of Toxoplasma gondii and Pneumocystis carinii in animal models. Parasitol Res. 1995;81(4):296-301. PubMed PMID: 7624286. 10: Brun-Pascaud M, Chau F, Garry L, Jacobus D, Derouin F, Girard PM. Combination of PS-15, epiroprim, or pyrimethamine with dapsone in prophylaxis of Toxoplasma gondii and Pneumocystis carinii dual infection in a rat model. Antimicrob Agents Chemother. 1996 Sep;40(9):2067-70. PubMed PMID: 8878582; PubMed Central PMCID: PMC163474. 11: Dhople AM. In vivo activity of epiroprim, a dihydrofolate reductase inhibitor, singly and in combination with dapsone, against Mycobacterium leprae. Int J Antimicrob Agents. 2002 Jan;19(1):71-4. PubMed PMID: 11814771. 12: Dhople AM. Antimicrobial activities of dihydrofolate reductase inhibitors, used singly or in combination with dapsone, against Mycobacterium ulcerans. J Antimicrob Chemother. 2001 Jan;47(1):93-6. PubMed PMID: 11152437. 13: Sayama H, Komura H, Kogayu M. Application of hybrid approach based on empirical and physiological concept for predicting pharmacokinetics in humans--usefulness of exponent on prospective evaluation of predictability. Drug Metab Dispos. 2013 Feb;41(2):498-507. doi: 10.1124/dmd.112.048819. Epub 2012 Dec 3. PubMed PMID: 23209193. 14: Gangjee A, Vasudevan A, Queener SF. Synthesis and biological evaluation of nonclassical 2,4-diamino-5-methylpyrido[2,3-d]pyrimidines with novel side chain substituents as potential inhibitors of dihydrofolate reductases. J Med Chem. 1997 Feb 14;40(4):479-85. PubMed PMID: 9046338. 15: Walzer PD, Runck J, Steele P, White M, Linke MJ, Sidman CL. Immunodeficient and immunosuppressed mice as models to test anti-Pneumocystis carinii drugs. Antimicrob Agents Chemother. 1997 Feb;41(2):251-8. PubMed PMID: 9021175; PubMed Central PMCID: PMC163697. 16: Walzer PD, Foy J, Steele P, White M. Synergistic combinations of Ro 11-8958 and other dihydrofolate reductase inhibitors with sulfamethoxazole and dapsone for therapy of experimental pneumocystosis. Antimicrob Agents Chemother. 1993 Jul;37(7):1436-43. PubMed PMID: 8363372; PubMed Central PMCID: PMC187990.